Lung cancer is a complex disease that can differ significantly from one person to another. The most appropriate treatment depends on the type of lung cancer, stage of disease, tumour characteristics, molecular findings and the person's overall health.
At Precision Oncology Clinic, lung cancer care focuses on understanding the individual diagnosis before deciding on a treatment approach. Depending on the clinical situation, treatment may involve surgery, radiation therapy, chemotherapy, targeted therapy, immunotherapy or a combination of treatments.
Personalised cancer care based on diagnosis, stage and tumour biologyLung cancer develops when abnormal cells in the lung grow uncontrollably and form a tumour. Some lung cancers can remain localised within the lung, while others may spread to nearby lymph nodes or other parts of the body.
Lung cancer is not a single disease. Different types have different biological characteristics and may respond differently to treatment. This is why establishing the exact diagnosis is an important first step in planning treatment.
Non-small cell lung cancer (NSCLC) is the most common broad category of lung cancer. It includes several subtypes, including adenocarcinoma and squamous cell carcinoma.
Small cell lung cancer (SCLC) is a distinct type that can behave differently from NSCLC and often requires a different treatment strategy.
Some lung cancers contain molecular changes that may help identify targeted treatment options. Biomarker testing can therefore be an important part of treatment planning in appropriate patients.
Two people diagnosed with lung cancer may require completely different treatment plans. The cancer type, stage and molecular characteristics all contribute to treatment decisions.
A treatment recommendation should not be based on the scan alone. Pathology, imaging, staging and relevant biomarker information are considered together.
Your age, general health, lung function, previous treatments and personal circumstances may also influence which treatment options are appropriate.
Modern lung cancer treatment increasingly combines information from pathology, imaging and tumour biology to help select the most appropriate treatment for each patient.
Depending on the diagnosis, treatment may involve one treatment modality or a combination of different approaches. The goal is to select treatment that addresses the cancer while also considering the patient's overall health, expected benefits, potential side effects and quality of life.
Lung cancer may not cause noticeable symptoms in its early stages. When symptoms do occur, they can vary depending on the location and extent of the tumour. Many of these symptoms can also be caused by infections, chronic lung conditions or other non-cancerous problems.
A cough that does not settle, becomes progressively worse or changes from a person's usual pattern should be evaluated, particularly when other symptoms are present.
Blood in sputum or coughing up blood should not be ignored and warrants medical assessment.
New or unexplained shortness of breath may occur when a tumour affects the airways or when there are other changes affecting the lungs.
Persistent or unexplained chest discomfort or pain can occur with lung cancer, although it has many other possible causes.
Recurrent pneumonia or chest infections, particularly in the same area, may sometimes require further investigation.
Unintentional weight loss, reduced appetite or unexplained weakness can occur with several illnesses, including cancer.
Ongoing tiredness or reduced energy without an obvious explanation can accompany lung cancer and many other medical conditions.
Persistent hoarseness or a change in voice may require assessment, particularly when it does not improve.
New or persistent wheezing can have several causes and should be evaluated when it is unexplained or continues despite treatment.
A symptom does not automatically mean lung cancer. However, persistent, unexplained or progressively worsening respiratory symptoms should be assessed rather than repeatedly treated without understanding the underlying cause.
A persistent or changing cough, coughing up blood, unexplained breathlessness, recurring chest infections, persistent chest pain, unexplained weight loss or other symptoms that do not improve as expected.
Lung cancer can occur in people with different backgrounds, but certain exposures and personal factors are associated with a higher risk.
Having a risk factor does not mean that a person will develop lung cancer, and not everyone diagnosed with lung cancer has an obvious risk factor.
Persistent symptoms should therefore be assessed based on the individual clinical situation rather than relying only on smoking history.
In selected people at sufficiently high risk, lung cancer screening with low-dose CT can detect lung abnormalities before symptoms develop.
Screening is not the same as diagnostic testing. Screening is intended for people who meet specific risk and eligibility criteria and do not already have symptoms suggesting a possible cancer. People with symptoms require appropriate clinical evaluation rather than simply relying on a screening test.
Cough, breathlessness, chest pain and fatigue are common symptoms with many possible causes, including infections, asthma, chronic obstructive pulmonary disease and other respiratory or cardiac conditions.
The presence of a symptom alone cannot establish a diagnosis of lung cancer. A doctor may recommend examination, imaging, laboratory tests or further investigations depending on the clinical findings.
Lung cancers are broadly divided into two major groups: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). These cancers differ in their microscopic appearance, behaviour and treatment approach.
NSCLC accounts for the majority of lung cancers. It includes several different subtypes, and treatment is influenced by the subtype, stage and molecular characteristics of the tumour.
SCLC is a different type of lung cancer that tends to grow and spread more quickly than NSCLC. Its treatment strategy is therefore different and commonly involves systemic treatment, with radiation used in selected situations.
Identifying the specific subtype helps the oncology team understand the tumour and select appropriate diagnostic and treatment strategies.
Adenocarcinoma is a common form of NSCLC and can occur in people who have never smoked as well as in current or former smokers. It often begins in cells involved in producing substances such as mucus.
Squamous cell carcinoma often develops in the larger airways and has a strong association with tobacco exposure. The diagnosis is established through pathological examination.
Less common forms and tumours with unusual pathological characteristics may require additional pathological evaluation to establish the diagnosis accurately.
Imaging can show a suspicious mass or abnormal area in the lung, but imaging alone usually cannot establish the exact type of cancer. Tissue examination is often required to confirm the diagnosis.
Depending on the location of the abnormality and the clinical situation, tissue may be obtained through procedures such as bronchoscopy, needle biopsy or surgery.
The safest and most appropriate method depends on the tumour's location, size, accessibility and the patient's overall condition.
For many patients with advanced or metastatic NSCLC, molecular testing can provide important information about the biology of the tumour and whether a targeted treatment may be appropriate.
Depending on the type and stage of lung cancer, testing may assess for alterations or markers such as:
PD-L1 testing may also be relevant in selected patients. The appropriate tests depend on the histological type, stage, treatment setting and current clinical guidelines. Not every patient requires every biomarker test.
Two patients with the same broad diagnosis may have different molecular characteristics. One tumour may contain an actionable genetic alteration, while another may not.
This information can influence whether targeted therapy, immunotherapy, chemotherapy, radiation, surgery or a combination of treatments is considered. Biomarker results are interpreted together with the cancer stage, symptoms, previous treatment and overall health.
Diagnosing lung cancer involves more than identifying a mass on a scan. Doctors combine clinical assessment, imaging, tissue examination and, when appropriate, molecular testing to establish the diagnosis and understand the extent of disease.
Your symptoms, medical history, smoking or exposure history, physical examination and overall health are considered as part of the initial assessment.
A chest X-ray or CT scan may identify a suspicious lung abnormality and provide information about its location and appearance.
A biopsy may be required to confirm whether the abnormality is cancer and to determine its pathological type.
Additional imaging may be recommended to determine whether cancer has spread to lymph nodes or distant organs.
In appropriate NSCLC cases, molecular and biomarker testing can help identify treatment options based on tumour biology.
The complete information can be reviewed by relevant specialists to develop an appropriate treatment strategy.
Imaging helps doctors understand the location, size and extent of a suspected lung tumour and look for involvement of lymph nodes or other organs.
A CT scan of the chest provides detailed images of the lungs, airways, surrounding structures and lymph nodes. It is commonly used when a lung abnormality requires further evaluation.
PET-CT combines metabolic information with anatomical imaging. It may be used for staging selected lung cancers and can help identify areas of active disease elsewhere in the body.
MRI may be recommended for particular clinical questions, including assessment of the brain or structures near the chest when clinically appropriate.
Depending on the type and stage of lung cancer and the clinical situation, brain imaging may be recommended as part of staging or evaluation of neurological symptoms.
A suspicious lung lesion on imaging does not by itself establish the exact cancer type. When tissue confirmation is required, the biopsy approach is selected according to the location of the lesion and the patient's clinical circumstances.
A bronchoscope can be used to examine the airways and obtain tissue or fluid samples from suitable lesions.
In selected cases, a needle may be guided through the chest to obtain a sample from a lung lesion, often using imaging guidance.
Lymph nodes may be sampled when determining whether cancer has spread to regional lymph nodes is important for staging.
Surgery may sometimes be required when other biopsy methods cannot provide an adequate or appropriate tissue diagnosis.
Why adequate tissue matters: In addition to confirming the diagnosis, an adequate tissue sample may be needed for immunohistochemistry and molecular or biomarker testing. The testing strategy depends on the pathological diagnosis and clinical setting.
Staging describes how far the cancer has developed and whether it has spread beyond the original tumour. For many lung cancers, the TNM system is used as part of the staging process.
Describes the primary tumour, including its size and involvement of nearby structures.
Describes whether regional lymph nodes contain cancer and their location.
Describes whether cancer has spread to distant parts of the body.
The exact stage depends on the cancer type and detailed TNM findings. Broadly, stages describe increasing extent of disease, but individual stage categories can contain important subdivisions.
Cancer is generally confined to the lung and has not spread to regional lymph nodes.
The tumour may be larger or involve nearby structures or regional lymph nodes, depending on the specific TNM pattern.
Disease may involve more extensive regional lymph-node disease or nearby structures and is divided into several clinical and pathological categories.
Cancer has spread to distant parts of the body or presents with other findings that place it in the metastatic stage.
Staging is individual. A stage label alone does not determine the exact treatment. Histological type, molecular findings, overall health, operability and other clinical factors are also considered when developing a treatment plan.
Knowing the extent of lung cancer helps the oncology team decide whether treatment should focus on removing the tumour, controlling disease in the chest, treating cancer throughout the body, or combining several approaches.
For example, some early-stage lung cancers may be considered for surgery or focused radiation treatment, while locally advanced disease may require combined treatment. Metastatic disease is generally managed with systemic treatments selected according to the cancer type and its molecular or biomarker characteristics.
Lung cancer treatment is selected according to the type and stage of cancer, tumour biology, overall health and whether the disease can be treated with a local approach or requires treatment throughout the body.
Treatment may involve one or more approaches, including surgery, radiation therapy, chemotherapy, targeted therapy and immunotherapy. In some situations, these treatments are given together or sequentially.
The aim may be to remove the cancer, control disease, reduce the risk of recurrence, relieve symptoms or maintain quality of life, depending on the individual clinical situation.
Surgery may be considered for selected patients, particularly when the cancer is localised or can be removed safely. Depending on the tumour and lung function, surgery may involve removal of part of the lung or an entire lobe.
Radiation uses high-energy radiation to destroy or control cancer cells. It may be used with curative intent, together with other treatments, or to relieve symptoms caused by advanced disease.
Chemotherapy uses medicines that act on rapidly dividing cancer cells. It may be used alone or in combination with surgery, radiation, immunotherapy or other systemic treatments.
Targeted medicines are designed to act on specific molecular changes found in some lung cancers. They are generally considered when appropriate biomarkers are identified.
Immunotherapy helps the immune system recognise and attack cancer cells. Its suitability depends on factors such as the cancer type, stage, previous treatment and relevant biomarkers.
Lung cancer may require a combination of treatments. For example, chemotherapy and radiation may be combined for selected locally advanced cancers, while systemic and local treatments may be used at different stages of care.
Treatment varies considerably between early-stage, locally advanced and metastatic lung cancer. The following is a broad overview; the actual treatment plan depends on the individual diagnosis.
| Disease Setting | Treatment Approaches That May Be Considered | Main Considerations |
|---|---|---|
| Early-stage disease | Surgery or, in selected patients who cannot undergo surgery, focused radiation such as stereotactic body radiation therapy (SBRT). | Tumour location, size, lung function, operability and overall health. |
| Stage II / selected resectable disease | Surgery may be combined with systemic treatment before or after surgery depending on the specific diagnosis and treatment setting. | Lymph-node involvement, tumour characteristics and molecular findings. |
| Locally advanced disease | Radiation and systemic treatment may be combined in selected patients, with treatment tailored to the extent of disease. | Regional lymph-node involvement, resectability and patient's ability to tolerate treatment. |
| Metastatic disease | Systemic treatments such as targeted therapy, immunotherapy, chemotherapy or appropriate combinations may be considered. Local treatments may also have a role in selected circumstances. | Molecular alterations, PD-L1 status, sites of spread, symptoms, previous treatment and overall health. |
Surgery is an important treatment option for selected patients with lung cancer that can be safely removed. The decision depends on the cancer stage, location, lung function and general health.
Depending on the tumour and the surgeon's assessment, minimally invasive approaches such as video-assisted thoracoscopic surgery (VATS) or robotic-assisted surgery may be considered.
The choice of surgical approach depends on anatomy, tumour characteristics, available expertise and patient factors.
Radiation therapy can be used in different stages of lung cancer. Modern techniques are designed to deliver radiation accurately while limiting exposure to surrounding healthy tissues.
In selected early-stage patients who are not suitable for surgery, stereotactic body radiation therapy may provide a focused treatment option.
Radiation may also be combined with systemic treatment for selected locally advanced disease.
Radiation may also be used to relieve symptoms caused by cancer, such as pain or symptoms from disease affecting particular areas of the body.
Systemic treatment travels through the bloodstream and can act on cancer cells throughout the body. It is particularly important when lung cancer has spread beyond the primary tumour.
Important: Not every patient needs every type of treatment. The sequence and combination of therapies are determined after reviewing the complete clinical, pathological, imaging and molecular information.
Lung cancer treatment is increasingly guided by the individual characteristics of the tumour rather than by stage alone. Pathology, molecular findings, imaging and the patient's overall health are considered together before selecting treatment.
This approach is particularly important in advanced non-small cell lung cancer, where specific molecular alterations or immune-related markers may influence the choice of systemic treatment.
Establish the pathological type and subtype of lung cancer.
Assess the extent of disease using appropriate imaging and staging investigations.
Consider relevant molecular alterations and biomarkers.
Match appropriate local and systemic treatments to the patient's clinical situation.
Targeted therapy is designed to act on specific molecular alterations that help cancer cells grow or survive. These medicines are different from conventional chemotherapy and are used when an appropriate target is identified.
Targeted treatment may be considered when testing identifies a molecular alteration for which an appropriate targeted medicine is available.
Depending on the clinical setting, testing may evaluate alterations involving genes or pathways such as:
Immunotherapy uses medicines that help the body's immune system recognise and respond to cancer cells. It has become an important treatment option for selected patients with lung cancer.
PD-L1 expression may help inform treatment decisions in certain settings. However, PD-L1 is only one part of the clinical assessment.
Cancer type, stage, molecular alterations, previous treatment and the patient's overall condition are also considered.
Chemotherapy remains an important treatment for several forms and stages of lung cancer. It may be used alone or combined with radiation, surgery, immunotherapy or targeted treatment, depending on the diagnosis.
In selected patients, systemic treatment may be given before surgery to reduce the risk of recurrence and address cancer cells that may not be visible on scans.
Additional systemic treatment may be recommended after surgery for selected patients based on the tumour stage, pathology and other risk factors.
Chemotherapy may be used to control advanced disease, sometimes together with immunotherapy or other systemic treatments.
Systemic chemotherapy is an important component of treatment for small cell lung cancer and may be combined with immunotherapy or radiation in selected settings.
Lung cancer can involve disease that is both local and systemic. Combining treatments can therefore allow doctors to address different aspects of the disease.
Selected patients may receive systemic treatment before or after surgery to improve disease control.
Radiation may be combined with chemotherapy or other systemic treatment in selected locally advanced cancers.
Certain advanced lung cancers may be treated with a combination of immunotherapy and chemotherapy when clinically appropriate.
In selected metastatic situations, treatment directed at a particular tumour site may be combined with systemic therapy.
There is no single treatment that is suitable for every person with lung cancer. Treatment recommendations are based on the complete clinical picture.
The goal is not simply to use more treatments. The aim is to select the treatment or combination of treatments that is appropriate for the specific cancer and the individual patient, while balancing expected benefit, potential side effects and quality of life.
Lung cancer can cause different symptoms depending on the location and extent of the tumour. Some people may have few or no symptoms in the early stages, while others may develop persistent respiratory or general symptoms.
Important: These symptoms do not necessarily mean that a person has lung cancer. Many respiratory conditions can cause similar symptoms. Persistent, unexplained or worsening symptoms should be assessed by a qualified healthcare professional.
Side effects vary according to the treatment being used, the dose, the combination of medicines and the individual's health. Supportive care is an important part of lung cancer treatment.
Tiredness can occur during cancer treatment. Rest, appropriate physical activity, nutrition and management of contributing problems may help.
Some systemic treatments can cause nausea or changes in appetite. Medicines and dietary strategies may help control these symptoms.
Some treatments can temporarily affect blood-cell counts, requiring monitoring and appropriate medical management.
Certain targeted therapies and other treatments can cause skin or nail changes that may require specific care.
Immunotherapy works differently from chemotherapy and targeted therapy. Because it activates the immune system, it can sometimes cause inflammation in healthy organs.
Some immune-related side effects can become serious if they are not recognised and treated promptly.
Patients receiving immunotherapy should report new, persistent or worsening symptoms to their oncology team rather than assuming they are a normal part of treatment.
Supportive care focuses on maintaining comfort, function and quality of life throughout the cancer journey. It can be provided alongside active cancer treatment.
Follow-up does not end when the initial treatment is completed. Regular review helps monitor recovery, treatment effects and signs of recurrence or progression when applicable.
Symptoms, physical health and recovery are assessed during follow-up appointments.
Follow-up scans may be recommended according to the cancer type, treatment and clinical situation.
Long-term or delayed effects of surgery, radiation or systemic treatment may need ongoing assessment.
The follow-up plan is individualised according to the cancer type, stage, treatment and risk of recurrence.
Patients undergoing lung cancer treatment should seek medical advice when they develop new or worsening symptoms, particularly when symptoms are sudden, severe or significantly different from their usual condition.
New cough, increasing breathlessness, persistent diarrhoea, severe rash, jaundice, unusual fatigue or other unexplained symptoms should be reported promptly because they may occasionally indicate an immune-related adverse effect.
Understanding the diagnosis, treatment options and next steps can help patients and families make informed decisions about lung cancer care.
There is no single treatment that is best for every patient. Treatment depends on the type and stage of lung cancer, tumour characteristics, molecular findings, overall health and whether the cancer has spread. Surgery, radiation therapy, chemotherapy, targeted therapy and immunotherapy may be used individually or in combination.
Some early-stage lung cancers can potentially be treated with curative intent. For more advanced disease, treatment may focus on controlling the cancer, extending survival, relieving symptoms and maintaining quality of life. The outlook varies considerably between individuals.
No. Surgery is appropriate only for selected patients. Factors such as cancer stage, tumour location, lung function, overall health and whether the tumour can be safely removed are considered. Radiation or systemic treatment may be more appropriate in other situations.
Molecular testing examines cancer cells for specific genetic or molecular changes that may influence treatment. Identifying an actionable alteration can help determine whether a targeted therapy may be appropriate.
Certain biomarkers and molecular alterations can influence treatment selection, particularly in advanced non-small cell lung cancer. Testing may help identify patients who could benefit from targeted therapy or specific immunotherapy approaches.
Chemotherapy acts against rapidly dividing cells through medicines that circulate throughout the body. Targeted therapies are designed to act on specific molecular alterations involved in cancer growth and are used when an appropriate target is identified.
No. Immunotherapy is appropriate only in certain clinical situations. The decision depends on factors including the type and stage of cancer, biomarker results, previous treatments and the patient's overall health.
Lung cancer can recur after treatment, although the risk varies according to the cancer type, stage, tumour characteristics and treatment received. Regular follow-up helps monitor for recurrence and manage long-term effects of treatment.
An oncology consultation can help review the pathology, imaging, stage and other available test results and explain appropriate treatment options. Early specialist assessment can be particularly important when treatment decisions need to be made promptly.
Yes. Modern lung cancer treatment increasingly considers the individual's cancer biology, molecular findings, stage, overall health and treatment goals. This can help the oncology team select an appropriate combination and sequence of treatments.
If you or a loved one has been diagnosed with lung cancer, a specialist oncology consultation can help you understand the diagnosis, stage and available treatment options.
Book an Oncology ConsultationMedical Disclaimer: The information provided on this page is intended for general educational purposes only and should not be considered a substitute for professional medical advice, diagnosis or treatment. Lung cancer treatment must be individualised based on the patient's diagnosis, stage, pathology, molecular findings and overall health. Please consult a qualified oncologist for personalised medical advice.
Precision Oncology Clinic, the best Cancer Clinic in Bangalore, located in Vijayanagar. Book appointment!
©2024. All Rights Reserved. Precision Oncology Clinic
By HAAPS
Book Appointment